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PPP to 69,231 US-$ PPP. A co-morbid conduct disorder was reported to be the most 
influential factor for increased health care costs. All CEA analysed psychotherapy 
interventions. While CEA reporting cost per avoided parasuicide event indicated 
favourable incremental cost effectiveness ratios, CEA reporting cost per quality-
adjusted life years (QALY) indicated just weak cost-effectiveness. ConClusions: 
BPD is associated with high costs. Available COI provide a first insight into the 
structure of cost and its predictors. There are no CEA regarding medication for 
BPD. Evidence regarding the cost-effectiveness of psychotherapy interventions is 
ambiguous. Future research should promote the understanding of the economic 
aspects of BPD and determine the societal value of its treatment. In this context 
high methodical standards are particularly important.
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objeCtives: To calculate the annual health insurance treatment cost of epilepsy 
disease in Hungary. Methods: The data derive from the financial database of the 
Hungarian National Health Insurance Fund Administration (NHIFA), the only health 
care financing agency in Hungary. We analyzed the health insurance treatment 
cost and the number of patients for the year 2010. The following cost categories 
were included into the study: out-patient care, in-patient care, CT-MRI, PET, home 
care, transportation, general practitioner, drugs and medical devices. Results: 
The Hungarian National Health Insurance Fund Administration spent 6.341 billion 
Hungarian Forint (HUF) (23.026 million EUR) for the treatment of epilepsy patients. 
The annual average expenditure per patient was 41900 HUF (152.1 EUR) while the 
average expenditure per one inhabitant was 633 HUF (2.3 EUR). Major cost drivers 
were pharmaceuticals (6.3 % of total health insurance costs), general practitioners 
(13.1 %) and acute inpatient care (11.4 %). The number of patients with epilepsy was 
151 per 100000 populations. We found the highest patient number in pharmaceuti-
cal budget (151357 patients), out-patient care (131280 patients) and general practi-
tioners (86704 patients). ConClusions: Epilepsy disease represents a significant 
burden for the health insurance system. Pharmaceutical treatment is the major 
cost driver for epilepsy disease in Hungary.
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objeCtives: To compare health care resource utilization (HRU) and costs among 
children/adolescents with attention deficit/hyperactivity disorder (ADHD) in Quebec, 
Canada, who received an atypical antipsychotic (AAP) as either augmentation or 
alternative therapy to stimulant, before vs. after initiating the AAP. Methods: 
Patients (6–17 years) with ≥ 2 documented ADHD diagnoses (ICD-9 codes: 314.0–
314.9), who used stimulants for ≥ 30 days and either switched to an AAP or aug-
mented stimulants with an AAP, were identified in Quebec’s health care database, 
the Régie de l’assurance maladie du Québec between 03/2007 and 02/2012. Patients 
with a documented diagnosis for which AAPs are indicated were excluded. All-
cause and ADHD-related HRU and costs (from a public payer’s perspective in 2012 
Canadian dollars) were compared between the 6-month period before (pre-index) 
and after (post-index) patients’ first AAP prescription claim. Results: A total of 453 
children/adolescents met the inclusion criteria (54.5% switched from stimulants to 
AAPs and 45.5% augmented stimulants with AAPs). The mean age was 10.4 years 
(SD= 2.5) and 25.4% were female. The most prevalent documented mental comorbidi-
ties in the pre-index period were adjustment reaction (7.1%), anxiety disorder (5.1%), 
and learning disability (4.4%). Risperidone (81.7%) and quetiapine (16.3%) were the 
most common AAPs initiated. Compared to the pre-index period, patients incurred, 
on average, more all-cause outpatient visits and costs (3.2 vs. 4.6; $207 vs. $303), 
prescription fills and costs (13.3 vs. 22.2; $710 vs. $889), total medical costs ($644 vs. 
$1,096), and total health care costs ($1,354 vs. $1,985) (all p< 0.05) during the post-
index period. Similarly, ADHD-related total health care costs ($835 vs. $1,269; p< 0.05) 
were higher during the post-index period; all-cause and ADHD-related total health 
care costs increased by 46.6% and 52.0%, respectively. ConClusions: Children/
adolescents with ADHD, who received an AAP as either augmentation or alternative 
therapy to stimulant, incurred higher HRU and costs after AAP initiation, mostly 
through ADHD-related HRU.
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objeCtives: The goal of our research was to assess and calculate the costs of 
antipsychotic treatment of schizophrenia patients in Hungary, using the database 
of the National Health Insurance Fund (NHIF). Based on the results of a recently 
published study using real world data (Bitter et al. 2013.) we focused especially on 
the costs linked to the early medication discontinuation and poor adherence of 
schizophrenia patients. Methods: In Hungary all medicines which are purchased 
with reimbursement are documented in the centralized register of the NHIF since 
1998. We analyzed the Payer’s database taking into account the time to treatment 
discontinuation results of the Bitter et al. study. We calculated the yearly aver-
age costs of schizophrenia treatment both per patient, and both per substance 
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objeCtives: To gather data concerning burden of schizophrenia in seven Central 
and Eastern European (CEE) countries (Croatia, Estonia, Hungary, Poland, Serbia, 
Slovakia, Slovenia) taking into account: epidemiology, clinical guidelines and rec-
ommendations, current standards of care, costs of illness, resource utilisation, 
health-related quality of life (HRQoL), stigmatisation and discrimination related 
to schizophrenia. The project focused on negative symptoms (NS). Methods: A 
targeted search was performed focused on publications issued from 1995 onwards 
and indexed in the following databases: PubMed, Cochrane Library, and Centre for 
Review and Dissemination. Moreover, searches for literature in local languages 
from each country of interest were conducted. Results: Fourteen reviews related 
to schizophrenia epidemiology were identified and revealed that the mean inci-
dence of schizophrenia varied greatly from 0.04 to 0.58 per 1,000 population and 
lifetime prevalence from 0.4% to 1.4%. At least one negative symptom was found 
to be present in 57.6% of schizophrenia patients and in 50–90% of individuals expe-
riencing their first schizophrenia episode. Primary NS were observed in 10–30% 
of patients. Mortality of schizophrenia patients was greater than in the general 
population (Standardised Mortality Ratio varies between 2.58 and 4.3), potentially 
due to increased suicide risk, effect of illness on lifestyle and environment, and 
side effects of disease treatment. Identified guidelines indicate a role for second-
generation antipsychotics in NS treatment, nevertheless the development of novel 
therapeutic approaches should be pursued actively. Thirty-seven primary publica-
tions identified from the seven CEE countries which relate to HRQoL of patients 
and caregivers revealed that the disease greatly affects HRQoL of hospitalised 
patients and has a significant negative impact on caregivers’ QoL. ConClusions: 
The literature review confirmed that schizophrenia is one of the most common 
and burdensome mental illnesses, with NS present in a relatively large percent-
age of patients.
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objeCtives: To assess the excess direct medical costs associated with a diagnosis of 
attention-deficit/hyperactivity disorder (ADHD) in Germany. Methods: Nordbaden 
is a region in Southwestern Germany with a population of 2.74 million. Regional 
sociodemographics and health care provider density are well understood and reflect, 
with few exceptions, respective national averages. The Nordbaden database cov-
ers the total regional population insured by SHI (2.24 million lives), integrating 
administrative data from the organization of physicians registered with statutory 
health insurance (SHI) and SHI, allowing patient-centered evaluation of health care 
utilization and direct medical cost for years 2003 to 2009. Patients with a diagnosis 
of ADHD were compared to a control group matched by age, gender, and type of 
health insurance within SHI. Here we report on years 2006-2009, as nonpharmaco-
logical therapy-related cost data were not fully available for earlier years. Results: 
Average annual total cost per ADHD patient increased from € 897 in 2006 to € 1,006 in 
2009 (controls, € 261 in 2006 and € 337 in 2009). Cost per patient correlated positively 
with age, and female patients were generally more costly than males (total as well as 
excess costs). Increasing severity and comorbidity were also associated with higher 
costs per patient. Physician services constituted the major cost component (on 
average, overall, € 653 per case in 2009), followed by pharmacological therapy (€ 330 
in 2009). ConClusions: The average excess cost (from the perspective of German 
SHI) per ADHD patient (over all age groups and irrespective of gender, compared 
to matched controls) was € 669 per year in 2009. Extrapolation from the regional to 
the national level suggests annual outpatient treatment costs attributable to ADHD 
in the magnitude of € 500 million (2009), from the payer’s perspective of SHI. This 
estimate compares to total annual expenditures for health services by German SHI 
of € 160 billion in 2009.
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objeCtives: The borderline personality disorder (BPD) is a common mental dis-
order. It is frequently associated with various mental co-morbidities and causes a 
fundamental loss of functioning. Furthermore, economically relevant consequences 
such as high utilization of inpatient and emergency room treatment or reduced 
productivity at work have been reported. The aim of this study is to present the 
existing health economic evidence regarding BPD and to point out implications 
for further research. Methods: We performed a systematic literature search in 
MEDLINE, EMBASE, PsycInfo and NHSEED to identify cost-of-illness studies (COI), 
cost-effectiveness analyses (CEA) and other cost studies (OCS) regarding BPD. Cost 
data were inflated to the year 2010 and converted into US-$ using purchasing power 
parities (PPP). Quality assessment of the studies was performed by means of a 
standardised quality checklist. Results: We identified three COI, eight CEA and 
six OCS. The methodical quality was moderate. Depending on study perspective 
and considered cost categories cost per patient and year ranged from 18,306 US-$ 
